Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael H Alderman

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 29, 2013
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHATWilliam Phillips, Linda B Piller, Jeff D Williamson, et al.
Statistics in Medicine|September 11, 2012
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?Michael Proschan, Charles E Ford, Jeffrey A Cutler, et al.
Kidney International|February 12, 2004
The impact of serum uric acid on cardiovascular outcomes in the LIFE studyAud Høieggen, Michael H Alderman, Sverre E Kjeldsen, et al.
Hypertension (Dallas, Tex. : 1979)|March 21, 2012
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trialMichael H Alderman, Linda B Piller, Charles E Ford, et al.
Archives of Internal Medicine|May 13, 2009
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analysesJackson T Wright, Jeffrey L Probstfield, William C Cushman, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 4, 2002
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)William C Cushman, Charles E Ford, Jeffrey A Cutler, et al.
European Heart Journal|October 4, 2020
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intakeMartin O'Donnell, Andrew Mente, Michael H Alderman, et al.
Hypertension (Dallas, Tex. : 1979)|July 26, 2006
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trialFrans H H Leenen, Chuke E Nwachuku, Henry R Black, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 13, 2012
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialWilliam C Cushman, Barry R Davis, Sara L Pressel, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 29, 2013
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHATWilliam Phillips, Linda B Piller, Jeff D Williamson, et al.
Statistics in Medicine|September 11, 2012
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?Michael Proschan, Charles E Ford, Jeffrey A Cutler, et al.
Kidney International|February 12, 2004
The impact of serum uric acid on cardiovascular outcomes in the LIFE studyAud Høieggen, Michael H Alderman, Sverre E Kjeldsen, et al.
Hypertension (Dallas, Tex. : 1979)|March 21, 2012
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trialMichael H Alderman, Linda B Piller, Charles E Ford, et al.
Archives of Internal Medicine|May 13, 2009
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analysesJackson T Wright, Jeffrey L Probstfield, William C Cushman, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 4, 2002
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)William C Cushman, Charles E Ford, Jeffrey A Cutler, et al.
European Heart Journal|October 4, 2020
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intakeMartin O'Donnell, Andrew Mente, Michael H Alderman, et al.
Hypertension (Dallas, Tex. : 1979)|July 26, 2006
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trialFrans H H Leenen, Chuke E Nwachuku, Henry R Black, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 13, 2012
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialWilliam C Cushman, Barry R Davis, Sara L Pressel, et al.
Pageof 12